3-Nitropropionic acid: A mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease

Journal of Neurochemistry

Volumn 95, Issue 6, 2005, Pages 1521-1540

  Brouillet, Emmanuel ^a,c   Jacquard, Carine ^a   Bizat, Nicolas ^a   Blum, David ^b  

^a SERVICE HOSPITALIER FRÉDÉRIC JOLIOT   (France)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^c SERVICE HOSPITALIER FRÉDÉRIC JOLIOT   (France)

Author keywords

Adenosine; Calpain; Dopamine; Glutamate; Mitochondria; Neurodegenerative disease; Neuroprotection

Indexed keywords

3 NITROPROPIONIC ACID; ADENOSINE; CALPAIN; CANNABINOID; DOPAMINE; GLUTAMIC ACID; HUNTINGTIN; STRESS ACTIVATED PROTEIN KINASE; TOXIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CELL DEATH; CONTROLLED STUDY; ENVIRONMENTAL FACTOR; GENE MUTATION; GENETIC MODEL; GLIA CELL; HUNTINGTON CHOREA; MITOCHONDRIAL DNA DISORDER; NEUROCHEMISTRY; NEUROMODULATION; NEUROPATHOLOGY; NONHUMAN; PATHOGENESIS; PATHOLOGICAL ANATOMY; PATHOPHYSIOLOGY; PRIMATE; PRIORITY JOURNAL; RAT; REGULATORY MECHANISM; REVIEW; STRIATONIGRAL DEGENERATION;

ANIMALS; HUMANS; HUNTINGTON DISEASE; MITOCHONDRIA; NEOSTRIATUM; NERVE DEGENERATION; NERVE TISSUE PROTEINS; NEUROTOXINS; NITRO COMPOUNDS; NUCLEAR PROTEINS; PHENOTYPE; PROPIONIC ACIDS;

ANIMALIA; PRIMATES;

EID: 29144468251     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2005.03515.x     Document Type: Review

References (199)

1. Albin R. L. and Greenamyre J. T. (1992) Alternative excitotoxic hypotheses. Neurology 42, 733-738.
2. Alexi T., Hughes P. E., Knusel B. and Tobin A. J. (1998) Metabolic compromise with systemic 3-nitropropionic acid produces striatal apoptosis in Sprague-Dawley rats but not in BALB/c ByJ mice. Exp. Neurol. 153, 74-93.
3. Alfinito P. D., Wang S. P., Manzino L., Rijhsinghani S., Zeevalk G. D. and Sonsalla P. K. (2003) Adenosinergic protection of dopaminergic and GABAergic neurons against mitochondrial inhibition through receptors located in the substantia nigra and striatum, respectively. J. Neurosci. 23, 10 982-10 987.
4. de Almeida L. P., Ross C. A., Zala D., Aebischer P. and Deglon N. (2002) Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size, huntingtin expression levels, and protein length. J. Neurosci. 22, 3473-3483.
5. Almeida S., Domingues A., Rodrigues L., Oliveira C. R. and Rego A. C. (2004) FK506 prevents mitochondrial-dependent apoptotic cell death induced by 3-nitropropionic acid in rat primary cortical cultures. Neurobiol. Dis 17, 435-444.
6. Alston T. A., Mela L. and Bright H. J. (1977) 3-Nitropropionate, the toxic substance of Indigofera, is a suicide inactivator of succinate dehydrogenase. Proc. Natl Acad. Sci. USA 74, 3767-3771.
7. Arrasate M., Mitra S., Schweitzer E. S., Segal M. R. and Finkbeiner S. (2004) Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431, 805-810.
8. Bae B. I., Xu H., Igarashi S. et al. (2005) p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease. Neuron 47, 29-41.
9. Bantubungi K., Jacquard C., Greco A. et al. (2005) Minocycline in phenotypic models of Huntington's disease. Neurobiol. Dis. 18, 206-217.
10. Beal M. F. (1992) Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann. Neurol. 31, 119-130.
11. Beal M. F. (1995) Mitochondrial Dysfunction and Oxidative Damage in Neurological Diseases. Neuroscience Intelligence Unit, R. G. Landes Company. Springer Verlag, Heidelberg.
12. Beal M. F. and Ferrante R. J. (2004) Experimental therapeutics in transgenic mouse models of Huntington's disease. Nat. Rev. Neurosci. 5, 373-384.
13. Beal M. F., Kowall N. W., Ellison D. W., Mazurek M. F., Swartz K. J. and Martin J. B. (1986) Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 321, 168-171.
14. Beal M. F, Brouillet E., Jenkins B. G., Ferrante R. J., Kowall N. W., Miller J. M., Storey E., Srivastava R., Rosen B. R. and Hyman B. T. (1993) Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J. Neurosci. 13, 4181-4192.
15. Bezprozvanny I. and Hayden M. R. (2004) Deranged neuronal calcium signaling and Huntington disease. Biochem. Biophys. Res. Commun. 322, 1310-1317.
16. Bizat N., Hermel J. M., Boyer F., Jacquard C., Creminon C., Ouary S., Escartin C., Hantraye P., Kajewski S. and Brouillet E. (2003a) Calpain is a major cell death effector in selective striatal degeneration induced in vivo by 3-nitropropionate: implications for Huntington's disease. J. Neurosci. 23, 5020-5030.
17. Bizat N., Hermel J. M., Humbert S., Jacquard C., Creminon C., Escartin C., Saudou F., Krajewski S., Hantraye P. and Brouillet E. (2003b) In vivo calpain/caspase cross-talk during 3-nitropropionic acid-induced striatal degeneration: implication of a calpain-mediated cleavage of active caspase-3. J. Biol. Chem. 278, 43 245-43 253.
18. Bizat N., Galas M., Jacquard C., Boyer F., Schiffmann S. N., Hantraye P., Blum D. and Brouillet E. (2005) Neuroprotective effects on zVAD-fink against 3-nitropropionic acid involves direct inhibition of calpain. Neuropharmacology 49, 695-702.
19. Blum D., Gall D., Cuvelier L. and Schiffmann S. N. (2001a) Topological analysis of striatal lesions induced by 3-nitropropionic acid in the Lewis rat. Neuroreport 12, 1769-1772.
20. Blum D., Torch S., Lambeng N., Nissou M., Benabid A. L., Sadoul R. and Verna J. M. (2001b) Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog. Neurobiol. 65, 135-172.
21. Blum D., Galas M. C., Gall D., Cuvelier L. and Schiffmann S. N. (2002a) Striatal and cortical neurochemical changes induced by chronic metabolic compromise in the 3-nitropropionic model of Huntington's disease. Neurobiol. Dis. 10, 410-426.
22. Blum D., Gall D., Galas M. C., d'Alcantara P., Bantubungi K. and Schiffinann S. N. (2002b) The adenosine A1 receptor agonist adenosine amine congener exerts a neuroprotective effect against the development of striatal lesions and motor impairments in the 3-nitropropionic acid model of neurotoxicity. J. Neurosci. 22, 9122-9133.
23. Blum D., Galas M. C., Pintor A. et al. (2003a) A dual role of adenosine A2A receptors in 3-nitropropionic acid-induced striatal lesions: implications for the neuroprotective potential of A2A antagonists. J. Neurosci. 23, 5361-5369.
24. Blum D., Mourez R., Galas M. C., Popoli P. and Schiffmann S. N. (2003b) Adenosine receptors and Huntington's disease: implications for pathogenesis and therapeutics. Lancet Neurol. 2, 366-374.
25. Blum D., Galas M. C., Cuvelier L. and Schiffmann S. N. (2004) Chronic intoxication with 3-nitropropionic acid in rats induces the loss of striatal dopamine terminals without affecting nigral cell viability. Neurosci. Lett. 354, 234-238.
26. Bogdanov M. B., Ferrante R. J., Kuemmerle S., Klivenyi P. and Beal M. F. (1998) Increased vulnerability to 3-nitropropionic acid in an animal model of Huntington's disease. J. Neurochem. 71, 2642-2644.
27. Borlongan C. V., Koutouzis T. K., Randall T. S., Freeman T. B., Cahill D. W. and Sanberg P. R. (1995) Systemic 3-nitropropionic acid: behavioral deficits and striatal damage in adult rats. Brain Res. Bull. 36, 549-556.
28. Brennan W. A. Jr, Bird E. D. and Aprille J. R. (1985) Regional mitochondrial respiratory activity in Huntington's disease brain. J. Neurochem. 44, 1948-1950.
29. Brouillet E., Jenkins B. G., Hyman B. T., Ferrante R. J., Kowall N. W., Srivastava R., Roy D. S., Rosen B. R. and Beal M. F. (1993) Age-dependent vulnerability of the striatum to the mitochondrial toxin 3-nitropropionic acid. J. Neurochem. 60, 356-359.
30. Brouillet E., Hantraye P., Ferrante R. J., Dolan R., Leroy-Willig A., Kowall N. W. and Beal M. F. (1995) Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc. Natl Acad. Sci. USA 92, 7105-7109.
31. Brouillet E., Guyot M. C., Mittoux V., Altairac S., Conde F., Palfi S. and Hantraye P. (1998) Partial inhibition of brain succinate dehydrogenase by 3-nitropropionic acid is sufficient to initiate striatal degeneration in rat. J. Neurochem. 70, 794-805.
32. Brouillet E., Conde F., Beal M. F. and Hantraye P. (1999) Replicating Huntington's disease phenotype in experimental animals. Prog. Neurobiol. 59, 427-468.
33. Browne S. E., Bowling A. C., MacGarvey U., Baik M. J., Berger S. C., Muqit M. M., Bird E. D. and Beal M. F. (1997) Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann. Neurol. 41, 646-653.
34. Butterworth J., Yates C. M. and Reynolds G. P. (1985) Distribution of phosphate-activated glutaminase, succinic dehydrogenase, pyruvate dehydrogenase and gamma-glutamyl transpeptidase in post-mortem brain from Huntington's disease and agonal cases. J. Neurol. Sci. 67, 161-171.
35. Calabresi P., Gubellini P., Picconi B., Centonze D., Pisani A., Bonsi P., Greengard P., Hipskind R. A., Borrelli E. and Bernardi G. (2001) Inhibition of mitochondrial complex II induces a long-term potentiation of NMDA-mediated synaptic excitation in the striatum requiring endogenous dopamine. J. Neurosci. 21, 5110-5120.
36. Canals J. M., Pineda J. R., Torres-Peraza J. F., Bosch M., Martin-Ibanez R., Munoz M. T., Mengod G., Ernfors P. and Alberch J. (2004) Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington's disease. J. Neurosci. 24, 7727-7739.
37. Carter R. J., Lione L. A., Humby T., Mangiarini L., Mahal A., Bates G. P., Dunnett S. B. and Morton A. J. (1999) Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J. Neurosci. 19, 3248-3257.
38. Cattaneo E. (2003) Dysfunction of wild-type huntingtin in Huntington disease. News Physiol. Sci. 18, 34-37.
39. Charvin D., Vanhoutte P., Pages C., Borelli E. and Caboche J. (2005) Unraveling a role for dopamine in Huntington's disease: dual role of reactive oxygen species and D2 receptor stimulation. Proc. Natl Acad. Sci. USA 102, 12 218-12 223.
40. Choo Y. S., Johnson G. V., MacDonald M., Detloff P. J. and Lesort M. (2004) Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. Hum. Mol. Genet. 13, 1407-1420.
41. Coles C. J., Edmondson D. E. and Singer T. P. (1979) Inactivation of succinate dehydrogenase by 3-nitropropionate. J. Biol. Chem. 254, 5161-5167.
42. 1H-NMR spectroscopy study of metabolic impairment in primates chronically treated with the succinate dehydrogenase inhibitor 3-nitropropionic acid. Neurobiol. Dis. 6, 259-268.
43. Dautry C., Vaufrey F., Brouillet E., Bizat N., Henry P. G., Conde F., Bloch G. and Hantraye P. (2000) Early N-acetylaspartate depletion is a marker of neuronal dysfunction in rats and primates chronically treated with the mitochondrial toxin 3-nitropropionic acid. J. Cereb. Blood Flow Metab. 20, 789-799.
44. Deglon N., Palfi S., Jarraya B., Bloch J., Conde F., Brouillet E., Aebischer P. and Hantraye P. (2004) Choreiform movements associated with intraneuronal aggregates and striatal pathology following lentiviral overexpression of mutant huntingtin in non-human primates, in SfN Meeting, October 22-27 2004. Society for Neuroscience, Washington, DC.
45. DiFiglia M., Sapp E., Chase K. O., Davies S. W., Bates G. P., Vonsattel J. P. and Aronin N. (1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277, 1990-1993.
46. Dragatsis I., Levine M. S. and Zeitlin S. (2000) Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nat. Genet. 26, 300-306.
47. Duan W., Guo Z. and Mattson M. P. (2000) Participation of par-4 in the degeneration of striatal neurons induced by metabolic compromise with 3-nitropropionic acid. Exp. Neurol. 165, 1-11.
48. El Massioui N., Ouary S., Cheruel F., Hantraye P. and Brouillet E. (2001) Perseverative behavior underlying attentional set-shifting deficits in rats chronically treated with the neurotoxin 3-nitropropionic acid. Exp. Neurol. 172, 172-181.
49. Eradiri O. L. and Starr M. S. (1999) Striatal dopamine depletion and behavioural sensitization induced by methamphetamine and 3-nitropropionic acid. Eur. J. Pharmacol. 386, 217-226.
50. Erecinska M. and Nelson D. (1994) Effects of 3-nitropropionic acid on synaptosomal energy and transmitter metabolism: relevance to neurodegenerative brain diseases. J. Neurochem. 63, 1033-1041.
51. Escartin C., Brouillet E., Hermel J., Deglon N., Bonvento G. and Hantraye P (2004) Overexpression of ciliary neurotrophic factor induced by lentiviral gene transfer in vivo leads to a sustained activation of astrocytes associated with a local decrease in brain metabolism, in SfN Meeting, October 22-27 2004. Society for Neuroscience, Washington, DC. Online, San Diego.
52. Fernagut P. O., Diguet E., Jaber M., Bioulac B. and Tison F. (2002) Dopamine transporter knock-out mice are hypersensitive to 3-nitropropionic acid-induced striatal damage. Eur. J. Neurosci. 15, 2053-2056.
53. Ferrante R. J., Kowall N. W., Beal M. F., Martin J. B., Bird E. D. and Richardson E. P. Jr (1987) Morphologic and histochemical characteristics of a spared subset of striatal neurons in Huntington's disease. J. Neuropathol. Exp. Neurol. 46, 12-27.
54. Ferrante R. J., Gutekunst C. A., Persichetti F., McNeil S. M., Kowall N. W., Gusella J. F., MacDonald M. E., Beal M. F. and Hersch S. M. (1997) Heterogeneous topographic and cellular distribution of huntingtin expression in the normal human neostriatum. J. Neurosci. 17, 3052-3063.
55. Fink J. S., Kalda A., Ryu H., Stack E. C., Schwarzschild M. A., Chen J. F. and Ferrante R. J. (2004) Genetic and pharmacological inactivation of the adenosine A2A receptor attenuates 3-nitropropionic acid-induced striatal damage. J. Neurochem. 88, 538-544.
56. Fontaine M. A., Geddes J. W., Banks A. and Butterfield D. A. (2000) Effect of exogenous and endogenous antioxidants on 3-nitropionic acid-induced in vivo oxidative stress and striatal lesions: insights into Huntington's disease. J. Neurochem. 75, 1709-1715.
57. Frim D. M., Simpson J., Uhler T. A., Short M. P., Bossi S. R., Breakefield X. O. and Isacson O. (1993) Striatal degeneration induced by mitochondrial blockade is prevented by biologically delivered NGF. J. Neurosci. Res. 35, 452-458.
58. Fu Y., He F., Zhang S., Huang J., Zhang J. and Jiao X. (1995) 3-Nitropropionic acid produces indirect excitotoxic damage to rat striatum. Neurotoxicol. Teratol. 17, 333-339.
59. Gabrielson K. L., Hogue B. A., Bohr V. A. et al. (2001) Mitochondrial toxin 3-nitropropionic acid induces cardiac and neurotoxicity differentially in mice. Am. J. Pathol. 159, 1507-1520.
60. Gafhi J. and Ellerby L. M. (2002) Calpain activation in Huntington's disease. J. Neurosci. 22, 4842-4849.
61. Galas M. C., Bizat N., Cuvelier L., Bantubungi K., Brouillet E., Schiffmann S. N. and Blum D. (2004) Death of cortical and striatal neurons induced by mitochondrial defect involves differential molecular mechanisms. Neurobiol. Dis. 15, 152-159.
62. Garcia M., Vanhoutte P., Pages C., Besson M. J., Brouillet E. and Caboche J. (2002) The mitochondrial toxin 3-nitropropionic acid induces striatal neurodegeneration via a c-Jun N-terminal kinase/c-Jun module. J. Neurosci. 22, 2174-2184.
63. Garcia M., Charvin D. and Caboche J. (2004) Expanded huntingtin activates the c-Jun terminal kinase/c-Jun pathway prior to aggregate formation in striatal neurons in culture. Neuroscience 127, 859-870.
64. Garcia O. and Massieu L. (2003) Glutamate uptake inhibitor 1-transpyrrolidine 2,4-dicarboxylate becomes neurotoxic in the presence of subthreshold concentrations of mitochondrial toxin 3-nitropropionate: involvement of mitochondrial reducing activity and ATP production. J. Neurosci. Res. 74, 956-966.
65. Gauthier L. R., Charrin B. C., Borrell-Pages M. et al. (2004) Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 118, 127-138.
66. Ghorayeb I., Fernagut P. O., Aubert I., Bezard E., Poewe W., Wenning G. K. and Tison F. (2000) Toward a primate model of 1-dopa-unresponsive parkinsonism mimicking striatonigral degeneration. Mov. Disord. 15, 531-536.
67. Gianfriddo M., Melani A., Turchi D., Giovannini M. G. and Pedata F. (2004) Adenosine and glutamate extracellular concentrations and mitogen-activated protein kinases in the striatum of Huntington transgenic mice. Selective antagonism of adenosine A2A receptors reduces transmitter outflow. Neurobiol. Dis. 17, 77-88.
68. Glass M., Dragunow M. and Faull R. L. (2000) The pattern of neurodegeneration in Huntingdon's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience 97, 505-519.
69. Gould D. H. and Gustine D. L. (1982) Basal ganglia degeneration, myelin alterations, and enzyme inhibition induced in mice by the plant toxin 3-nitropropanoic acid. Neuropathol. Appl. Neurobiol. 8, 377-393.
70. Gould D. H., Wilson M. P. and Hamar D. W. (1985) Brain enzyme and clinical alterations induced in rats and mice by nitroaliphatic toxicants. Toxicol. Lett. 27, 83-89.
71. Gourfinkel-An I., Cancel G., Trottier Y. et al. (1997) Differential distribution of the normal and mutated forms of huntingtin in the human brain. Ann. Neurol. 42, 712-719.
72. Grafton S. T., Mazziotta J. C., Pahl J. J., St George-Hyslop P., Haines J. L., Gusella J., Hoffman J. M., Baxter L. R. and Phelps M. E. (1990) A comparison of neurological, metabolic, structural, and genetic evaluations in persons at risk for Huntington's disease. Ann. Neurol. 28, 614-621.
73. Greene J. G. and Greenamyre J. T. (1996) Bioenergetics and glutamate excitotoxicity. Prog. Neurobiol. 48, 613-634.
74. Greene J. G., Sheu S. S., Gross R. A. and Greenamyre J. T. (1998) 3-Nitropropionic acid exacerbates N-methyl-D-aspartate toxicity in striatal culture by multiple mechanisms. Neuroscience 84, 503-510.
75. Gu M., Gash M. T., Mann V. M., Javoy-Agid F., Cooper J. M. and Schapira A. H. (1996) Mitochondrial defect in Huntington's disease caudate nucleus. Ann. Neurol. 39, 385-389.
76. Gubellini P., Centonze D., Tropepi D., Bernardi G. and Calabresi P. (2004) Induction of corticostriatal LTP by 3-nitropropionic acid requires the activation of mGluR1/PKC pathway. Neuropharmacology 46, 761-769.
77. Guidetti P., Luthi-Carter R. E., Augood S. J. and Schwarc Z. R. (2004) Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease. Neurobiol. Dis. 17, 455-461.
78. Gunawardena S., Her L. S., Brusch R. G., Laymon R. A., Niesman I. R., Gordesky-Gold B., Sintasath L., Bonini N. M. and Goldstein L. S. (2003) Disruption of axonal transport by loss of huntingtin or expression of pathogenic polyQ proteins in Drosophila. Neuron 40, 25-40.
79. Gutekunst C. A., Li S. H., Yi H., Mulroy J. S., Kuemmerle S., Jones R., Rye D., Ferrante R. J., Hersch S. M. and Li X. J. (1999) Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J. Neurosci. 19, 2522-2534.
80. Guyot M. C., Palfi S., Stutzmann J. M., Maziere M., Hantraye P. and Brouillet E. (1997) Riluzole protects from motor deficits and striatal degeneration produced by systemic 3-nitropropionic acid intoxication in rats. Neuroscience 81, 141-149.
81. Hamilton B. F. and Gould D. H. (1987a) Correlation of morphologic brain lesions with physiologic alterations and blood-brain barrier impairment in 3-nitropropionic acid toxicity in rats. Acta Neuropathol. (Berl.) 74, 67-74.
82. Hamilton B. F. and Gould D. H. (1987b) Nature and distribution of brain lesions in rats intoxicated with 3-nitropropionic acid: a type of hypoxic (energy deficient) brain damage. Acta Neuropathol. (Berl.) 72, 286-297.
83. Harjes P. and Wanker E. E. (2003) The hunt for huntingtin function: interaction partners tell many different stories. Trends Biochem. Sci. 28, 425-433.
84. Harper P. (1991) Huntington's Disease. W. B. Saunders, London.
85. Hayden M. R., Martin W. R., Stoessl A. J. et al. (1986) Positron emission tomography in the early diagnosis of Huntington's disease. Neurology 36, 888-894.
86. He F., Zhang S., Qian F. and Zhang C. (1995) Delayed dystonia with striatal CT lucencies induced by a mycotoxin (3-nitropropionic acid). Neurology 45, 2178-2183.
87. Hedreen J. C. and Folstein S. E. (1995) Early loss of neostriatal striosome neurons in Huntington's disease. J. Neuropathol. Exp. Neurol. 54, 105-120.
88. 13C] NMR spectroscopy. J. Neurochem. 82, 857-866.
89. von Horsten S., Schmitt I., Nguyen H. P. et al. (2003) Transgenic rat model of Huntington's disease. Hum. Mol. Genet. 12, 617-624.
90. Ikonomidou C., Stefovska V. and Turski L. (2000) Neuronal death enhanced by N-methyl-D-aspartate antagonists. Proc. Natl Acad. Sci. USA 97, 12 885-12 890.
91. Janavs J. L. and Aminoff M. J. (1998) Dystonia and chorea in acquired systemic disorders. J. Neurol. Neurosurg Psychiatry 65, 435-445.
92. 1H NMR spectroscopy. Neurology 43, 2689-2695.
93. Jenkins B. G., Brouillet E., Chen Y. C., Storey E., Schulz J. B., Kirschner P., Beal M. F. and Rosen B. R. (1996) Non-invasive neurochemical analysis of focal excitotoxic lesions in models of neurodegenerative illness using spectroscopic imaging. J. Cereb. Blood Flow Metab. 16, 450-461.
94. 1H NMR spectroscopy studies of Huntington's disease: correlations with CAG repeat numbers. Neurology 50, 1357-1365.
95. Johnson J. R., Robinson B. L., Ali S. F. and Binienda Z. (2000) Dopamine toxicity following long term exposure to low doses of 3-nitropropionic acid (3-NPA) in rats. Toxicol. Lett. 116, 113-118.
96. Kiechle T., Dedeoglu A., Kubilus J., Kowall N. W., Beal M. F., Friedlander R. M., Hersch S. M. and Ferrante R. J. (2002) Cytochrome C and caspase-9 expression in Huntington's disease. Neuromol. Med. 1, 183-195.
97. Kim G. W. and Chan P. H. (2002) Involvement of superoxide in excitotoxicity and DNA fragmentation in striatal vulnerability in mice after treatment with the mitochondrial toxin, 3-nitropropionic acid. J. Cereb. Blood Flow Metab. 22, 798-809.
98. Kim G. W., Copin J. C., Kawase M., Chen S. F., Sato S., Gobbel G. T. and Chan P. H. (2000) Excitotoxicity is required for induction of oxidative stress and apoptosis in mouse striatum by the mitochondrial toxin, 3-nitropropionic acid. J. Cereb. Blood Flow Metab. 20, 119-129.
99. Koroshetz W. J., Jenkins B. G., Rosen B. R. and Beal M. F. (1997) Energy metabolism defects in Huntington's disease and effects of coenzyme Q10. Ann. Neurol. 41, 160-165.
100. Kuemmerle S., Gutekunst C. A., Klein A. M., Li X. J., Li S. H., Beal M. F., Hersch S. M. and Ferrante R. J. (1999) Huntington aggregates may not predict neuronal death in Huntington's disease. Ann. Neurol. 46, 842-849.
101. Kuhl D. E., Phelps M. E., Markham C. H., Metter E. J., Riege W. H. and Winter J. (1982) Cerebral metabolism and atrophy in Huntington's disease determined by 18FDG and computed tomographic scan. Ann. Neurol. 12, 425-434.
102. Laforet G. A., Sapp E., Chase K. et al. (2001) Changes in cortical and striatal neurons predict behavioral and electrophysiological abnormalities in a transgenic murine model of Huntington's disease. J. Neurosci. 21, 9112-9123.
103. Lastres-Becker I., Fezza F., Cebeira M., Bisogno T., Ramos J. A., Milone A., Fernandez-Ruiz J. and Di Marzo V. (2001) Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington's disease. Neuroreport 12, 2125-2129.
104. Lastres-Becker I., Gomez M., De Miguel R., Ramos J. A. and Fernandez-Ruiz J. (2002) Loss of carmabinoid CB(1) receptors in the basal ganglia in the late akinetic phase of rats with experimental Huntington's disease. Neurotox. Res. 4, 601-608.
105. Lastres-Becker I., Bizat N., Boyer P., Hantraye P., Fernandez-Rui Z. J. and Brouillet E. (2004) Potential involvement of carmabinoid receptors in 3-nitropropionic acid toxicity in vivo. Neuroreport 15, 2375-2379.
106. Lee F. S. and Chao M. V. (2001) Activation of Trk neurotrophin receptors in the absence of neurotrophins. Proc. Natl Acad. Sci. USA 98, 3555-3560.
107. Lee W. T., Shen Y. Z. and Chang C. (2000) Neuroprotective effect of lamotrigine and MK-801 on rat brain lesions induced by 3-nitropropionic acid: evaluation by magnetic resonance imaging and in vivo proton magnetic resonance spectroscopy. Neuroscience 95, 89-95.
108. Lee W. T., Yin H. S. and Shen Y. Z. (2002) The mechanisms of neuronal death produced by mitochondrial toxin 3-nitropropionic acid: the roles of N-methyl-D-aspartate glutamate receptors and mitochondrial calcium overload. Neuroscience 112, 707-716.
109. Leventhal L., Sortwell C. E., Hanbury R., Collier T. J., Kordower J. H. and Palfi S. (2000) Cyclosporin A protects striatal neurons in vitro and in vivo from 3-nitropropionic acid toxicity. J. Comp. Neurol. 425, 471-478.
110. Li J. Y, Plomann M. and Brundin P. (2003) Huntington's disease: a synaptopathy? Trends Mol. Med. 9, 414-420.
111. Li S. H. and Li X. J. (2004) Huntingtin-protein interactions and the pathogenesis of Huntington's disease. Trends Genet. 20, 146-154.
112. Lione L. A., Carter R. J., Hunt M. J., Bates G. P., Morton A. J. and Durrnett S. B. (1999) Selective discrimination learning impairments in mice expressing the human Huntington's disease mutation. J. Neurosci. 19, 10 428-10 437.
113. Liu Y. F. (1998) Expression of polyglutamine-expanded Huntingtin activates the SEK1-JNK pathway and induces apoptosis in a hippocampal neuronal cell line. J. Biol. Chem. 273, 28 873-28 877.
114. Liu Y. F., Deth R. C. and Devys D. (1997) SH3 domain-dependent association of huntingtin with epidermal growth factor receptor signaling complexes. J. Biol. Chem. 272, 8121-8124.
115. Lodi R., Schapira A. H., Manners D., Styles P., Wood N. W., Taylor D. J. and Warner T. T. (2000) Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy. Ann. Neurol. 48, 72-76.
116. Ludolph A. C., He F., Spencer P. S., Hammerstad J. and Sabri M. (1991) 3-Nitropropionic acid - exogenous animal neurotoxin and possible human striatal toxin. Can. J. Neurol. Sci. 18, 492-498.
117. Luthi-Carter R. and Cha J.-H. J. (2003) Mechanisms of transcriptional dysregulation in Huntington's disease. Clin. Neurosci. Res. 3, 165-177.
118. 2+ and respiratory chain complex II inhibition. J. Neurochem. 90, 1025-1035.
119. Mann V. M., Cooper J. M., Javoy-Agid F., Agid Y., Jenner P. and Schapira A. H. (1990) Mitochondrial function and parental sex effect in Huntington's disease. Lancet 336, 749.
120. Mantamadiotis T., Lemberger T., Bleckmann S. C. et al. (2002) Disruption of CREB function in brain leads to neurodegeneration. Nat. Genet. 31, 47-54.
121. Maragos W. F., Jakel R. J., Pang Z. and Geddes J. W. (1998) 6-Hydroxydopamine injections into the nigrostriatal pathway attenuate striatal malonate and 3-nitropropionic acid lesions. Exp. Neurol. 154, 637-644.
122. 3H]dopamine uptake into rat striatal synaptosomes. Biochem. Pharmacol. 63, 1499-1505.
123. Marti M., Mela F., Ulazzi L., Hanau S., Stocchi S., Paganini F., Beani L., Bianchi C. and Morari M. (2003) Differential responsiveness of rat striatal nerve endings to the mitochondrial toxin 3-nitropropionic acid: implications for Huntington's disease. Eur. J. Neurosci. 18, 759-767.
124. Martin-Aparicio E., Yamamoto A., Hernandez F., Hen R., Avila J. and Lucas J. J. (2001) Proteasomal-dependent aggregate reversal and absence of cell death in a conditional mouse model of Huntington's disease. J. Neurosci. 21, 8772-8781.
125. Massieu L., Del Rio P. and Montiel T. (2001) Neurotoxicity of glutamate uptake inhibition in vivo: correlation with succinate dehydrogenase activity and prevention by energy substrates. Neuroscience 106, 669-677.
126. Mazziotta J. C., Phelps M. E., Pahl J. J. et al. (1987) Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington's disease. N. Engl. J. Med. 316, 357-362.
127. McBride J. L., During M. J., Wuu J., Chen E. Y., Leurgans S. E. and Kordower J. H. (2003) Structural and functional neuroprotection in a rat model of Huntington's disease by viral gene transfer of GDNF. Exp. Neurol. 181, 213-223.
128. Menalled L. B. and Chesselet M. F. (2002) Mouse models of Huntington's disease. Trends Pharmacol. Sci. 23, 32-39.
129. de Mendonca A., Sebastiao A. M. and Ribeiro J. A. (1995) Inhibition of NMDA receptor-mediated currents in isolated rat hippocampal neurones by adenosine A1 receptor activation. Neuroreport 6, 1097-1100.
130. Mittoux V., Ouary S., Monville C. et al. (2002) Corticostriatopallidal neuroprotection by adenovirus-mediated ciliary neurotrophic factor gene transfer in a rat model of progressive striatal degeneration. J. Neurosci. 22, 4478-4486.
131. 2+i increase and cell damage in cultured rat cerebral endothelial cells. Brain Res. 956, 116-125.
132. Myers R. H., Vonsattel J. P., Stevens T. J., Cupples L. A., Richardson E. P., Martin J. B. and Bird E. D. (1988) Clinical and neuropathologic assessment of severity in Huntington's disease. Neurology 38, 341-347.
133. 2+, ATP, mitochondrial membrane potential, and calpain activity on the mechanism of neuron death induced by 3-nitropropionic acid. Neurochem. Int. 43, 89-99.
134. Naver B., Stub C., Moller M., Fenger K., Hansen A. K., Hasholt L. and Sorensen S. A. (2003) Molecular and behavioral analysis of the R6/1 Huntington's disease transgenic mouse. Neuroscience 122, 1049-1057.
135. Nishino H., Kumazaki M., Fukuda A. et al. (1997) Acute 3-nitropropionic acid intoxication induces striatal astrocytic cell death and dysfunction of the blood-brain barrier: involvement of dopamine toxicity. Neurosci. Res. 27, 343-355.
136. Nishino H., Nakajima K., Kumazaki M., Fukuda A., Muramatsu K., Deshpande S. B., Inubushi T., Morikawa S., Borlongan C. V. and Sanberg P. R. (1998) Estrogen protects against while testosterone exacerbates vulnerability of the lateral striatal artery to chemical hypoxia by 3-nitropropionic acid. Neurosci. Res. 30, 303-312.
137. Nishino H., Hida H., Kumazaki M., Shimano Y, Nakajima K., Shimizu H., Ooiwa T. and Baba H. (2000) The striatum is the most vulnerable region in the brain to mitochondrial energy compromise: a hypothesis to explain its specific vulnerability. J. Neurotrauma 17, 251-260.
138. Novelli A., Reilly J. A., Lysko P. G. and Henneberry R. C. (1988) Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced. Brain Res. 451, 205-212.
139. Novotny E. J. Jr, Singh G., Wallace D. C., Dorfman L. J., Louis A., Sogg R. L. and Steinman L. (1986) Leber's disease and dystonia: a mitochondrial disease. Neurology 36, 1053-1060.
140. Ohgoh M., Shimizu H., Ogura H. and Nishizawa Y. (2000) Astroglial trophic support and neuronal cell death: influence of cellular energy level on type of cell death induced by mitochondrial toxin in cultured rat cortical neurons. J. Neurochem. 75, 925-933.
141. Olsen C., Rustad A., Fonnum F., Paulsen R. E. and Hassel B. (1999) 3-Nitropropionic acid: an astrocyte-sparing neurotoxin in vitro. Brain Res. 850, 144-149.
142. Ouary S., Bizat N., Altairac S., Menetrat H., Mittoux V., Conde F., Hantraye P. and Brouillet E. (2000) Major strain differences in response to chronic systemic administration of the mitochondrial toxin 3-nitropropionic acid in rats: implications for neuroprotection studies. Neuroscience 97, 521-530.
143. Palfi S., Ferrante R. J., Brouillet E., Beal M. F., Dolan R., Guyot M. C., Peschanski M. and Hantraye P. (1996) Chronic 3-nitropropionic acid treatment in baboons replicates the cognitive and motor deficits of Huntington's disease. J. Neurosci. 16, 3019-3025.
144. Palfi S., Conde F., Riche D., Brouillet E., Dautry C., Mittoux V., Chibois A., Peschanski M. and Hantraye P. (1998) Fetal striatal allografts reverse cognitive deficits in a primate model of Huntington disease. Nat. Med. 4, 963-966.
145. Pang Z., Bondada V., Sengoku T., Siman R. and Geddes J. W. (2003) Calpain facilitates the neuron death induced by 3-nitropropionic acid and contributes to the necrotic morphology. J. Neuropathol. Exp. Neurol. 62, 633-643.
146. Panov A. V., Gutekunst C. A., Leavitt B. R., Hayden M. R., Burke J. R., Strittmatter W. J. and Greenamyre J. T. (2002) Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat. Neurosci. 5, 731-736.
147. Petersen A., Mani K. and Brundin P. (1999) Recent advances on the pathogenesis of Huntington's disease. Exp. Neurol. 157, 1-18.
148. Petersen A., Larsen K. E., Behi G. G., Romero N., Przedborski S., Brundin P. and Sulzer D. (2001) Expanded CAG repeats in exon 1 of the Huntington's
149. Popoli P., Betto P., Reggio R. and Ricciarello G. (1995) Adenosine A2A receptor stimulation enhances striatal extracellular glutamate levels in rats. Eur. J. Pharmacol. 287, 215-217.
150. Popoli P., Pintor A., Domenici M. R. et al. (2002) Blockade of striatal adenosine A2A receptor reduces, through a presynaptic mechanism, quinolinic acid-induced excitotoxicity: possible relevance to neuroprotective interventions in neurodegenerative diseases of the striatum. J. Neurosci. 22, 1967-1975.
151. Qin Z. H. and Gu Z. L. (2004) Huntingtin processing in pathogenesis of Huntington disease. Acta Pharmacol Sin. 25, 1243-1249.
152. Reynolds D. S., Carter R. J. and Morton A. J. (1998) Dopamine modulates the susceptibility of striatal neurons to 3-nitropropionic acid in the rat model of Huntington's disease. J. Neurosci. 18, 10 116-10 127.
153. Rigamonti D., Bauer J. H., De-Fraja C. et al. (2000) Wild-type huntingtin protects from apoptosis upstream of caspase-3. J. Neurosci. 20, 3705-3713.
154. Rigamonti D., Sipione S., Goffredo D., Zuccato C., Fossale E. and Cattaneo E. (2001) Huntingtin's neuroprotective activity occurs via inhibition of procaspase-9 processing. J. Biol. Chem. 276, 14 545-14 548.
155. Ruan Q., Lesort M., MacDonald M. E. and Johnson G. V. (2004) Striatal cells from mutant huntingtin knock-in mice are selectively vulnerable to mitochondrial complex II inhibitor-induced cell death through a non-apoptotic pathway. Hum. Mol. Genet. 13, 669-681.
156. Rudolphi K. A., Schubert P., Parkinson F. E. and Fredholm B. B. (1992) Neuroprotective role of adenosine in cerebral ischaemia. Trends Pharmacol. Sci. 13, 439-445.
157. Ryu J. K., Nagai A., Kim J., Lee M. C., McLarnon J. G. and Kim S. U. (2003) Microglial activation and cell death induced by the mitochondrial toxin 3-nitropropionic acid: in vitro and in vivo studies. Neurobiol. Dis 12, 121-132.
158. Saft C., Zange J., Andrich J., Muller K., Lindenberg K., Landwehrmeyer B., Vorgerd M., Kraus P. H., Przuntek H. and Schols L. (2005) Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease. Mov. Disord. 20, 674-679.
159. Sapp E., Kegel K. B., Aronin N., Hashikawa T., Uchiyama Y., Tohyama K., Bhide P. G., Vonsattel J. P. and DiFiglia M. (2001) Early and progressive accumulation of reactive microglia in the Huntington disease brain. J. Neuropathol. Exp. Neurol. 60, 161-172.
160. Saudou F., Finkbeiner S., Devys D. and Greenberg M. E. (1998) Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 95, 55-66.
161. Saulle E., Gubellini P., Picconi B. et al. (2004) Neuronal vulnerability following inhibition of mitochondrial complex II: a possible ionic mechanism for Huntington's disease. Mol. Cell. Neurosci. 25, 9-20.
162. Sawa A., Wiegand G. W., Cooper J., Margolis R. L., Sharp A. H., Lawler J. F. Jr, Greenamyre J. T., Snyder S. H. and Ross C. A. (1999) Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization. Nat. Med. 5, 1194-1198.
163. Schapira A. H. (2002) Primary and secondary defects of the mitochondrial respiratory chain. J. Inherit. Metab. Dis. 25, 207-214.
164. Schilling G., Becher M. W., Sharp A. H. et al. (1999) Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum. Mol. Genet. 8, 397-407.
165. Schulz J. B., Matthews R. T., Jenkins B. G., Ferrante R. J., Siwek D., Henshaw D. R., Cipolloni P. B., Mecocci P., Kowall N. W., Rosen B. R. and et al. (1995) Blockade of neuronal nitric oxide synthase protects against excitotoxicity in vivo. J. Neurosci. 15, 8419-8429.
166. Schulz J. B., Henshaw D. R., MacGarvey U. and Beal M. F. (1996) Involvement of oxidative stress in 3-nitropropionic acid neurotoxicity. Neurochem. Int. 29, 167-171.
167. Senut M. C., Suhr S. T., Kaspar B. and Gage F. H. (2000) Intraneuronal aggregate formation and cell death after viral expression of expanded polyglutamine tracts in the adult rat brain. J. Neurosci. 20, 219-229.
168. Singhrao S. K., Neal J. W., Morgan B. P. and Gasque P. (1999) Increased complement biosynthesis by microglia and complement activation on neurons in Huntington's disease. Exp. Neurol. 159, 362-376.
169. Song C., Zhang Y., Parsons C. G. and Liu Y. F. (2003) Expression of polyglutamine-expanded huntingtin induces tyrosine phosphorylation of N-methyl-D-aspartate receptors. J. Biol. Chem. 278, 33 364-33 369.
170. Sorbi S., Bird E. D. and Blass J. P. (1983) Decreased pyruvate dehydrogenase complex activity in Huntington and Alzheimer brain. Ann. Neurol. 13, 72-78.
171. Stahl W. L. and Swanson P. D. (1974) Biochemical abnormalities in Huntington's chorea brains. Neurology 24, 813-819.
172. Stefanova N., Puschban Z., Fernagut P. O., Brouillet E., Tison F., Reindl M., Jellinger K. A., Poewe W. and Wenning G. K. (2003) Neuropathological and behavioral changes induced by various treatment paradigms with MPTP and 3-nitropropionic acid in mice: towards a model of striatonigral degeneration (multiple system atrophy). Acta. Neuropathol. (Berl.) 106, 157-166.
173. Steffan J. S., Agrawal N., Pallos J. et al. (2004) SUMO modification of Huntingtin and Huntington's disease pathology. Science 304, 100-104.
174. Storgaard J., Komblit B. T., Zimmer J. and Gramsbergen J. B. (2000) 3-Nitropropionic acid neurotoxicity in organotypic striatal and corticostriatal slice cultures is dependent on glucose and glutamate. Exp. Neurol. 164, 227-235.
175. Strauss K. A. and Morton D. H. (2003) Type I glutaric aciduria, part 2: a model of acute striatal necrosis. Am. J. Med. Genet. C Semin. Med. Genet. 121, 53-70.
176. Sugars K. L. and Rubinsztein D. C. (2003) Transcriptional abnormalities in Huntington disease. Trends Genet. 19, 233-238.
177. Szatkowski M. and Attwell D. (1994) Triggering and execution of neuronal death in brain ischaemia: two phases of glutamate release by different mechanisms. Trends Neurosci. 17, 359-365.
178. Szebenyi G., Morfini G. A., Babcock A. et al. (2003) Neuropathogenic forms of huntingtin and androgen receptor inhibit fast axonal transport. Neuron 40, 41-52.
179. Tabrizi S. J., Cleeter M. W., Xuereb J., Taanman J. W., Cooper J. M. and Schapira A. H. (1999) Biochemical abnormalities and excitotoxicity in Huntington's disease brain. Ann. Neurol. 45, 25-32.
180. Tabrizi S. J., Workman J., Hart P. E., Mangiarini L., Mahal A., Bates G., Cooper J. M. and Schapira A. H. (2000) Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse. Ann. Neurol. 47, 80-86.
181. Tang T. S., Tu H., Chan E. Y., Maximov A., Wang Z., Wellington C. L., Hayden M. R. and Bezprozvanny I. (2003) Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor type 1. Neuron 39, 227-239.
182. Tavares R. G., Santos C. E., Tasca C. I., Wajner M., Souza D. O. and Dutra-Filho C. S. (2001) Inhibition of glutamate uptake into synaptic vesicles from rat brain by 3-nitropropionic acid in vitro. Exp. Neurol. 172, 250-254.
183. The Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72, 971-983.
184. Trottier Y., Devys D., Imbert G., Saudou F., An I., Lutz Y., Weber C., Agid Y., Hirsch E. C. and Mandel J. L. (1995) Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated form. Nat. Genet. 10, 104-110.
185. 1H nuclear magnetic resonance spectroscopy and biochemical characterization. Neuroscience 79, 819-826.
186. Turmaine M., Raza A., Mahal A., Mangiarini L., Bates G. P. and Davies S. W. (2000) Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease. Proc. Natl Acad. Sci. USA 97, 8093-8097.
187. Vis J. C., Schipper E., de Boer-van Huizen R. T., Verbeek M. M., de Waal R. M., Wesseling P., Ten Donkelaar H. J. and Kremer B. (2005) Expression pattern of apoptosis-related markers in Huntington's disease. Acta Neuropathol. (Berl.) 109, 321-328.
188. Wheeler V. C., Gutekunst C. A., Vrbanac V. et al. (2002) Early phenotypes that presage late-onset neurodegenerative disease allow testing of modifiers in Hdh CAG knock-in mice. Hum. Mol. Genet. 11, 633-640.
189. Yamamoto A., Lucas J. J. and Hen R. (2000) Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 101, 57-66.
190. Yang L., Sugama S., Mischak R. P., Kiaei M., Bizat N., Brouillet E., Joh T. H. and Beal M. F. (2004) A novel systemically active caspase inhibitor attenuates the toxicities of MPTP, malonate, and 3NP in vivo. Neurobiol. Dis. 17, 250-259.
191. Yang L., Calingasan N. Y., Chen J., Ley J. J., Becker D. A. and Beal M. F. (2005) A novel azulenyl nitrone antioxidant protects against MPTP and 3-nitropropionic acid neurotoxicities. Exp. Neurol. 191, 86-93.
192. Zeevalk G. D. and Nicklas W. J. (1990) Chemically induced hypoglycemia and anoxia: relationship to glutamate receptor-mediated toxicity in retina. J. Pharmacol. Exp. Ther. 253, 1285-1292.
193. 2+ block at the N-methyl-D-aspartate receptor underlies receptor activation during inhibition of neuronal metabolism. J. Neurochem. 59, 1211-1220.
194. Zeevalk G. D., Derr-Yellin E. and Nicklas W. J. (1995) Relative vulnerability of dopamine and GABA neurons in mesencephalic culture to inhibition of succinate dehydrogenase by malonate and 3-nitropropionic acid and protection by NMDA receptor blockade. J. Pharmacol. Exp. Ther. 275, 1124-1130.
195. Zeron M. M., Hansson O., Chen N., Wellington C. L., Leavitt B. R., Brundin P., Hayden M. R. and Raymond L. A. (2002) Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron 33, 849-860.
196. Zhang Y., Ona V. O., Li M., Drozda M., Dubois-Dauphin M., Przedborski S., Ferrante R. J. and Friedlander R. M. (2003) Sequential activation of individual caspases, and of alterations in Bcl-2 proapoptotic signals in a mouse model of Huntington's disease. J. Neurochem. 87, 1184-1192.
197. Zuccato C., Ciammola A., Rigamonti D. et al. (2001) Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 293, 493-498.
198. Zuccato C., Tartari M., Crotti A. et al. (2003) Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat. Genet. 35, 76-83.
199. Zuccato C., Liber D., Ramos C. and Tarditi A. (2005) Progressive loss of BDNF in a mouse model of Huntington's disease and rescue by BDNF delivery. Pharmacol. Res. 52, 133-139.